Kurzwirksame Insulinanaloga - Kritische Bewertung metaanalytischer Betrachtungen

Zusammenfassung

Kurzwirksame Insulinanaloga werden seit fast 10 Jahren bei der Behandlung des Diabetes mellitus Typ 1 und 2 eingesetzt. Es gibt eine ausführliche potentielle wissenschaftliche und praktische Evidenz für deren potentielle Überlegenheit gegenüber Normalinsulin. Daher werden diese Insuline bereits von den meisten führenden Fachgesellschaften in ihren Leitlinien empfohlen. Im klinischen Alltag stellen sie eine wesentliche Komponente des therapeutischen Portfolios dar, die insbesondere bei selektivem Einsatz zu einer deutlichen Verbesserung der Insulintherapie führen kann. Andererseits muss insbesondere auch in Deutschland dem wachsenden ökonomischen Druck Rechnung getragen werden. Dennoch darf die Kritik vorgetragen werden, dass Metaanalysen zu diesem Thema, die im Auftrag von Versicherungsträgern oder Regierungsbehörden erstellt worden sind, der wissenschaftlichen und Versorgungsrealität nicht gerecht werden. Aktuelle Metaanalysen zu den kurzwirksamen Insulinanaloga schließen entscheidende Vorteile von Insulinanaloga aus Analysen aus und vergleichen sehr heterogene Gruppen. Es wird nicht differenziert zwischen unterschiedlichen Hypoglykämieprävalenzen bei unterschiedlichen HbA _1c-Werten sowie konventioneller und intensivierter Therapie. Zudem schließt man positive Daten und positive Major-Studien aus, während Zulassungsstudien oder Studien mit gänzlich differenter Fragestellung zitiert werden. Zu kritisieren ist häufig auch die kurze Studiendauer. Die International Diabetes Federation (IDF) hat daher das Cochrane-Review aus dem Jahr 2005 methodisch abgelehnt, und auch aus dem IQWiG-Gutachten lassen sich keine reliablen therapeutische Empfehlungen ableiten.

Summary

Short-acting insulin analogs have for nearly ten years been prescribed for type 1 and 2 diabetes mellitus. There is extensive scientific and practical evidence of their being better than normal insulin. For this reason these insulins have been recommended in the guidelines of most leading specialist societies. In everyday practice they are an important component of the therapeutic portfolio which can produce an improvement in insulin treatment, especially of selective cases. On the other hand, there is growing economic pressure, especially in Germany, affecting their use. However, it must be critically asserted that those meta-analyses on insulin analogs, which have been commissioned by insurance companies or governmental organisations, do not do justice to their advantage. Current meta-analyses of short-acting insulin analogs exclude decisive advantages of insulin analogs from their analyses and compare highly heterogeneous groups. They do not distinguish between differing incidences of hypoglycemia associated with different HbA1c values as well as between conventional and intensive treatment. Furthermore positive data and positive major studies are excluded, while approval studies or trials with completely different aims are cited. Short study duration is also often neglected. As a result, the International Diabetes Federation (IDF) has rejected the Cochrane Review for 2005 for methodological reasons. Also, no recommendations can be derived from the recommendations of of the Institut für Qualitätssicherung und Wirtschaftlichkeit in der Medizin (IQWiG: Institute for Quality Assurance and Cost Effectiveness in Medicine). After critical assessment of meta-analyses the IDF concluded in its guidelines that insulin analogs should generally be used.

kurzwirksame Insulinanaloga - Insulin Lispro - Insulin Aspart - Insulin Glulisin

Short-acting insulin analogs - insulin lispro - insulin aspart - insulin glulisin

Literatur

• 1 Altuntas Y, Ozen B, Ozturk B. et al . Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure.  Diabetes Obes Metab. 2003;  5 371-378
• 2 Anderson J H, Brunelle R L, Keohane P. et al . Mealtime treatment with insulin analog improves postprandial hyperglycemia in patients with non-insulin-dependent diabetes mellitus. Multcenter Insulin Lispro Study Group.  Arch Intern Med. 1997;  157 1249-1255
• 3 Anderson J H, Brunelle R L, Koivisto V A, Trautmann V E, Vignati L, DiMarchi R. and the Insulin Lispro Study Group . Improved mealtime treatment of diabetes mellitus using an insulin analogue.  Clin Ther. 1997;  19 62-72
• 4 Bastyr E J, Yuang H, Brunelle R L, Vignati L, Cox D J, Kotsanos J G. Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro.  Diabetes Obes Metab. 2000;  2 39-46
• 5 Boehm B O, Home P D, Behrend C, Kamp N M, Lindholm A. Premixed insulin aspart 30 vs. Premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients.  Diabet Med. 2002;  19 393-399
• 6 Brunner G A, Hirschberger S, Sendlhofer G. et al . Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus.  Diabet Med. 2000;  17 371-375
• 7 Ciofetta M, Lalli C, Del Sindaco P. et al . Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.  Diabetes Care. 1999;  22 795-800
• 8 Clinical Study Report, HMR1964 - 3002. 26-week, multinational, multicenter, controlled open, 1:1 randomized, parallel, clinical trial to assess noninferiority between HMR1964 and regular human insulin injected subcutaneously in subjects with type 2 diabetes mellitus also using NPH insulin . 
• 9 Dailey G, Moses R G, Rosenstock J, Ways K. Insulin Glulisine provides improved glycemic control in patients with type 2 diabetes.  Diabetes Care. 2004;  27 2363-2368
• 10 EMEA. EPAR Insulin Lispro (Humalog) - Scientific discussion. http://www.emea.eu.int/humandocs/PDFs/EPAR/Humalog/060195en6.pdf Einsicht: 1.6.06 (Verfügbarkeit am 13.11.06 überprüft).
• 11 Gale E AM. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy.  Diabet Med. 2000;  17 209-214
• 12 Hedman C A, Orre-Pettersson A C, Lindstrom T, Arnqvist H J. Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes.  Clin Endocrinol. 2001;  55 107-112
• 13 Herz M, Profozioc V, Arora V, Smircic-Duvnjak L, Kovacevic I, Boras J. Effects of a mixed mixture of 25 % insulin lispro and 75 % NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes.  Cur Med Res Opin. 2002;  18 188-193
• 14 Herz M, Arora V, Campaigne B N, Scholtz H E, Potgieter M A, Mollentze W. Humalog Mix25 improves 24-hour profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus.  S Afr Med J. 2003;  93 219-223
• 15 Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson J H. Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients treated with insulin lispro.  Diabetes Care. 1997;  20 1827-1832
• 16 Institut für Qualitätssicherung und Wirtschaftlichkeit in der Medizin (IQWIG) .Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2 - Abschlussbericht. Version 1.0 15.12.2005: www.iqwig.de
• 17 Kurtzhals P, Schaffer L, Sorenson A. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.  Diabetes. 2000;  49 999-1005
• 18 Lalli C, Ciofetta M, Del Sindaco P. et al . Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.  Diabetes Care. 1999;  22 468-477
• 19 Orre-Petersson A C, Lindstrom T, Bergmark V, Arnqvist H J. The snack is critical for the blood glucose profile during treatment with regular insulin preprandially.  J Intern Med. 1999;  245 41-45
• 20 Paquot N, Roulin D, Schneiter P. et al . Effects of regular insulin or insulin lispro on glucose metabolism after an oral glucose load in patients with type 2 diabetes mellitus.  Diabetes Metab. 1998;  24 523-528
• 21 Plank J, Siebenhofer A, Berghold A. et al . Systematic review and meta-analysis of short-acting analogues in patients with diabetes mellitus.  Arch Intern Med. 2005;  165 1337-1344
• 22 Sackett D L, Rosenberg W M, Gray J A, Haynes R B, Richardson W S. Evidence based medicine: what it is and what it isn’t.  BMJ. 1996;  312 71-72
• 23 Scheen A J, Letiexhe M R, Lefebvre P J. Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme.  Diabetes Metab. 1999;  25 157-162
• 24 Schernthaner G, Wein W, Shnawa N, Bates P C, Birkett M A. Preprandial vs. postprandial insulin lispro - a comparative crossover trial in patients with type 1 diabetes.  Diabet Med. 2004;  21 279-284
• 25 Siebenhofer A, Plank J, Berghold A. et al . Short acting analogues versus regular human insulin in patients with diabetes mellitus.  Cochrane Database Syst Rev. 2006;  4 CD003287
• 26 Slieker L J, Brooke G S, DiMarchi R D. et al . Modifications in the B10 and B26 - 30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor.  Diabetologia. 1997;  40 S54-S61